Stock Market & Financial Investment News

StemCells spinal cord injury trial approved by Health CanadaStemCells announced that Health Canada has authorized the company to expand its Phase I/II clinical trial for chronic spinal cord injury into Canada. The Phase I/II trial, currently underway in Zurich, Switzerland, is designed to evaluate the safety and preliminary efficacy of the company's proprietary HuCNS-SC product candidate, or purified human neural stem cells, as a treatment for chronic spinal cord injury. With this authorization from Health Canada, the company is actively working to open one or more trial sites in Canada and begin screening patients.